Evotec Receives Pre-clinical Milestone Payment
News Aug 19, 2011
The milestone was achieved for the identification and selection of a compound to be advanced into pre-clinical development within an oncology programme and represents the fourteenth milestone achieved in this multi-year, multi-target collaboration.
Dr Mario Polywka, Chief Operating Officer of Evotec commented: “This important milestone achieved as part of our alliance with Boehringer Ingelheim is the fourth against an oncology target and importantly the first oncology programme to enter pre-clinical development for this collaboration. We continue to enjoy a fruitful scientific relationship with our colleagues at Boehringer in our efforts to drive new drug candidates to the clinic”.